Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $268.00 Price Target at Morgan Stanley

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price dropped by stock analysts at Morgan Stanley from $284.00 to $268.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target points to a potential upside of 15.92% from the stock’s current price.

Other research analysts have also issued research reports about the company. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a report on Friday, March 21st. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $280.00 to $328.00 in a research note on Monday, March 24th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $315.58.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY traded up $4.92 during trading hours on Friday, reaching $231.20. 322,428 shares of the company were exchanged, compared to its average volume of 857,028. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock’s 50-day moving average is $253.86 and its 200-day moving average is $258.62. The firm has a market cap of $30.08 billion, a PE ratio of -106.46 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ALNY. Larson Financial Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 73 shares in the last quarter. Park Square Financial Group LLC purchased a new position in Alnylam Pharmaceuticals in the fourth quarter worth $28,000. Whipplewood Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 71 shares during the period. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $33,000. Finally, OFI Invest Asset Management acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $35,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.